Table 1.
Grouped data from all 31 publications.
| Patient population | SARS‐Cov‐2 antibody positive/Total, % (N) | ||||
|---|---|---|---|---|---|
| ALL | Vaccine type | ||||
| mRNA | Inactivated viral | Vector | Unknown | ||
| Healthy controls | 92.9 (803/864) | 99.7 (633/635) | 72.4 (155/214) | 100 (2/2) | 100 (13/13) |
| Multiple sclerosis (Total) | 76.6 (1687/2203) | 78.2 (1549/1982) | 58.7 (88/150) | 85.7 (12/14) | 66.7 (38/57) |
| Untreated | 100 (215/215) | 100 (206/206) | – | – | 100 (9/9) |
| Interferon‐beta | 95.7 (179/187) | 99.4 (158/159) | 75.0 (21/28) | – | – |
| Glatiramer acetate | 95.0 (76/80) | 100 (65/65) | 73.3 (11/15) | – | – |
| Dimethyl fumarate/Diroximel fumarate | 98.5 (200/203) | 100 (176/176) | 88.9 (24/27) | – | – |
| Cladribine | 97.2 (173/178) | 99.4 (164/165) | 42.9 (3/7) | 100 (6/6) | – |
| Teriflunomide | 92.5 (111/120) | 100 (99/99) | 57.1 (12/21) | – | – |
| Natalizumab | 100 (189/189) | 100 (183/183) | – | – | 100 (6/6) |
| Alemtuzumab | 100 (20/20) | 100 (19/19) | 100 (1/1) | – | – |
| Sphingosine‐1 phosphate modulators (Total) | 71.9 (197/274) | 75.5 (179/237) | 36.4 (8/22) | 75.0 (6/8) | 57.1 (4/7) |
| Fingolimod | 72.7 (160/220) | 76.8 (152/198) | 36.4 (8/22) | 75.0 (6/8) | – |
| Unspecified | 68.5 (37/54) | 71.1 (32/45) | – | – | 57.1 (4/7) |
| Anti‐CD20 mAb (Total) | 44.4 (327/737) | 44.6 (300/673) | 27.6 (8/29) | – | 54.3 (19/35) |
| Ocrelizumab | 40.6 (226/556) | 39.5 (211/534) | – | – | 68.2 (15/22) |
| Rituximab | 60.5 (46/76) | 66.7 (42/63) | – | – | 30.8 (4/13) |
| Unspecified | 61.8 (47/76) | 61.8 (47/76) | 27.6 (8/29) | – | – |
Proportion of subjects who had positive antibody responses after COVID‐19 vaccination, listed by diagnosis and treatment, and vaccine type. Bolded titles are patient groupings.
pwMS, patients with multiple sclerosis; mAb, monoclonal antibody.